(Total Views: 374)
Posted On: 09/27/2022 6:57:35 PM
Post# of 8399
Courtesy of JGD, BIEL's New RecoveryRx Device initial FDA submission has been made
Looks like the official name is 'RecoveryRx XTRA'.
Keith Nalepka
• Following
Vice President of Sales and Marketing at BioElectronics Corporation, Board Member BioElectronics
8h • 8 hours ago
Very proud of our team, our Q-submission for our new Device RecoveryRX XTRA was received by the FDA. This platform has proven to reduce opioid consumption by 60% during the post op period and improve functionality and participation in PT&Rehab. As we have talked with potential partners, opportunity clearly exists in the orthopedic, breast augmentation and reconstruction spaces and all types of same day cases. We are continuing to disrupt the pain space with neuromodulation innovation, with no side effects, no interactions and efficacy. Thanks to our growing list of KOLS whose help has been incredible. #innovation #team #opportunity
https://www.linkedin.com/feed/update/urn:li:a...419786752/
The post immediately following this one on Linkedin also has info that was new to me. Keith refers to the 25 country Deal as OEM. I was thinking it was a Distribution Deal. OEM requires a larger commitment IMO.
Keith Nalepka
• Following
Vice President of Sales and Marketing at BioElectronics Corporation, Board Member BioElectronics
1mo • 1 month ago
We are small but pack a big punch, great company coverage @microcapdaily as we increase our global footprint and drive to revenue growth. Our OEM plan is clicking as we have added 25 new countries, SEA, APAC, CIS, Africa, MENA. Disruptive technology providing pain relief w/no interactions, lowering oral meds by 50+ percent
https://www.linkedin.com/feed/update/urn:li:a...175050241/
Looks like the official name is 'RecoveryRx XTRA'.
Keith Nalepka
• Following
Vice President of Sales and Marketing at BioElectronics Corporation, Board Member BioElectronics
8h • 8 hours ago
Very proud of our team, our Q-submission for our new Device RecoveryRX XTRA was received by the FDA. This platform has proven to reduce opioid consumption by 60% during the post op period and improve functionality and participation in PT&Rehab. As we have talked with potential partners, opportunity clearly exists in the orthopedic, breast augmentation and reconstruction spaces and all types of same day cases. We are continuing to disrupt the pain space with neuromodulation innovation, with no side effects, no interactions and efficacy. Thanks to our growing list of KOLS whose help has been incredible. #innovation #team #opportunity
https://www.linkedin.com/feed/update/urn:li:a...419786752/
The post immediately following this one on Linkedin also has info that was new to me. Keith refers to the 25 country Deal as OEM. I was thinking it was a Distribution Deal. OEM requires a larger commitment IMO.
Keith Nalepka
• Following
Vice President of Sales and Marketing at BioElectronics Corporation, Board Member BioElectronics
1mo • 1 month ago
We are small but pack a big punch, great company coverage @microcapdaily as we increase our global footprint and drive to revenue growth. Our OEM plan is clicking as we have added 25 new countries, SEA, APAC, CIS, Africa, MENA. Disruptive technology providing pain relief w/no interactions, lowering oral meds by 50+ percent
https://www.linkedin.com/feed/update/urn:li:a...175050241/
(5)
(0)
